GILD
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F2464854&ei=kXKaUuDfKbHr0QGFIA&usg=AFQjCNG_LlfHH3sO_IG2tUujhqe1RZGgHQ
Gilead Sciences, Inc. Completes Acquisition Of Pharmasset, Inc.
Tuesday, 17 Jan 2012 05:00pm EST
Gilead Sciences, Inc. announced the completion of the previously announced transaction for Royal Merger Sub II Inc., a wholly owned subsidiary of Gilead (Merger Sub II), , to acquire Pharmasset, Inc. for $137 per share in cash, or approximately $11.2 billion in the aggregate. On November 21, 2011, Gilead and Pharmasset announced that Pharmasset, Gilead and Royal Merger Sub Inc., a wholly-owned subsidiary of Gilead, had signed a definitive merger agreement pursuant to which a tender offer would be made. Pursuant to the merger agreement, Gilead, Merger Sub and Merger Sub II commenced a tender offer on December 6, 2011 to acquire all outstanding shares of Pharmasset at a price of $137 per share, net to the seller in cash. On January 12, 2012, Gilead announced that it had successfully completed the tender offer for all outstanding shares of common stock of Pharmasset. Pursuant to the terms of the merger agreement, Merger Sub II merged with and into Pharmasset on January 17, 2012. As a result of the completion of the merger, Pharmasset has become a wholly-owned subsidiary of Gilead and the common stock of Pharmasset will no longer be listed for trading on the NASDAQ Global Select Market, which is expected to take effect as of the close of market on January 17, 2012.Â 
